Objective
At present there is a mismatch between the extensive interest of the pharmaceutical industry to utilize enzyme technology in their production processes and the number of such processes commercially implemented. To overcome this mismatch c-LEcta aims at offering a smart platform of Plug & Play enzymes for the three most relevant enzyme classes (alcohol dehydrogenase, transaminases, and nitrilase). The platform will address the needs of the pharma industry for performing essential biocatalytic reactions suitable for the production of million fold applied chiral active pharmaceutical ingredients (APIs) like Atorvastatin, Rosuvastatin and Duloxetine. The API market is valued at $101.08 billion in 2010. The unique selling proposition of this platform is to comprise ~100 high quality enzymes per class, which are pre-qualified for a wide range of important structural patterns, applicable for synthesis processes and easily scalable. Therefore, the business opportunity is to take advantage of the great potential of biocatalysis since the platform allows matching timelines and cost requirements. Up to now such service was not available without contract signing and extensive development timelines and costs. The development cost may be reduced up to ~80% by using the new platform technology compared to the conventional work flow. In manufacturing, the total production cost of a product will be typically reduced by > 30%. The platform will be promoted to a medium volume market with high growth rates. c-LEcta will address the global market, which is going to be widened step-by-step. Subject matter of Phase 2 c-LEcta is to refine the design of the enzyme platform, to scale up the enzyme production, synthesis process development and pilot-scale application in order to demonstrate and to assure rapid availability of enzymes in pharma development and for subsequent commercialization.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- natural sciences chemical sciences organic chemistry alcohols
- natural sciences chemical sciences catalysis biocatalysis
- social sciences economics and business economics sustainable economy
- natural sciences biological sciences biochemistry biomolecules proteins enzymes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
04103 Leipzig
Germany
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.